FDA Approves Akynzeo for Chemo-Induced Nausea and Vomiting
October 10, 2014 – The US Food and Drug Administration (FDA) approved Akynzeo (netupitant and palonosetron) manufactured by Eisai, Inc. Akynzeo is used to help prevent chemotherapy-induced nausea and vomiting (CINV).
Akynzeo is a combination of Aloxi (palonosetron), which was approved in 2008 which prevents CINV during the first 24 hours following the start of chemotherapy, and netupitant which is a new medication that continues for up to 5 days to help prevent the delayed phase CINV. The launch date has not been announced.
If you have any questions you can contact our Client Services Call Center at 1-877-723-6005.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.